Compare Essex Property Trust, Inc. (ESS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Johnson & Johnson — how do they compare? Essex Property Trust, Inc. trades at $282.1 (market cap $18.15B), while Johnson & Johnson trades at $260.64 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 34.5× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ESS | JNJ | |
|---|---|---|
Market Cap | $18.15B | $626.09B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $267.24 |
52-Week Low | $239.61 | $172.78 |
Enterprise Value | $24.75B | $654.37B |
Dividend Yield | 3.93% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.92, down 0.46% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year guidance, reflecting strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is projected to moderate in 2026. Recent news highlights institutional buying by Amundi and recognition as a top GreenTech company.
The outlook is mixed: raised guidance and solid fundamentals support upside toward the $305.86 consensus price target, but technical weakness and a high debt load pose near-term risks. Investor sentiment is cautiously optimistic, with 40% of analysts rating the stock a Buy, though the bearish technical picture suggests potential volatility ahead.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
